DSR® Therapy
Heart Failure with Fluid Overload
Key Facts
About Sequana Medical
Sequana Medical is a commercial-stage innovator focused on transforming the management of fluid overload in severe chronic diseases. Its strategy is built on two proprietary platforms: the alfapump® system, which achieved a landmark U.S. FDA approval in December 2024 for recurrent ascites, and the DSR® (Direct Sodium Removal) therapy in development for heart failure. The company is executing a U.S. commercial launch for alfapump® while advancing its pipeline, aiming to establish a new standard of care across hepatology and cardiology.
View full company profile